Pioneers of Canada’s pharmaceutical sector, our leadership team consists of executives with experience at the world’s largest pharmaceutical companies.
Our expertise lies in pharmaceutical research and development, quality control operations, quality assurance and compliance. We are supported by world-class Medical Advisory and Clinical Advisory Boards, consisting of renowned physicians, psychiatrists, academics and field experts from Canada and abroad.
Corporate Governance & Compensation Committee Chair
Chief Scientific & Quality Officer
Vice President, Quality & Regulatory Affairs
Vice President, Clinical and Scientific Affairs
Vice President, Finance
Senior Director, Technology
Senior Site Director
Director of Pharmaceutical Research & Development
Director of Engineering
Senior Medical Consultant
Clinical Research Consultant
MBBS, PhD, FRCPC
T 416.291.2580 E email@example.com
Copyright © 2022 EmpowerPharm Inc. • All Rights Reserved
Former pharmaceutical executive at Novopharm Ltd. and President of Wampole Canada Inc. with over 15 years industry experience. Aubrey is a Canadian businessman, philanthropist as well as a Tony-Award® winning producer (MEMPHIS) who is also the principal of the Dancap Family Investment Office www.dancap.ca. Aubrey received an honorary Doctorate of Laws Degree (honoris causa) from Assumption University in 2008 and from Western University in 2019. He also received a Professional Achievement Award in 2015 from Western University. He is a Governor at Tel Aviv University, sits on the board of Avivagen. Aubrey received the Order of Canada in 2019.
Pharmaceutical industry veteran and senior manager with Novopharm Ltd. and Teva Pharmaceuticals with over 35 years experience. Peter has extensive experience in R&D program management, Decommissioning and Construction of manufacturing facilities and laboratories, Integration of companies, Technology Transfer, ERP selection and implementation. He was the Vice President responsible for the Integration of Novopharm Ltd. with Teva Pharmaceuticals. Peter then became Vice President of Business Process Improvement, responsible for the standardization of all business processes across North America for Teva Pharmaceuticals.
Peter obtained the Chartered Director (C.Dir.) designation from The Directors College at the DeGroote School of Business, McMaster University, 2022.
Peter received the designation Administrateur de sociétés certifié (ASC) from the University of Laval, in 2022.
Former President & CEO of Apotex Inc. with 55 years experience in the pharmaceutical industry including generic and branded. Jack spent 10 years in the pharmaceutical Industry as a detail sales representative for a Branded pharmaceutical company before moving over to Director of Government sales for ICN Canada in Montreal. He then joined Apotex Inc. as VP Sales & Marketing progressing to various roles including Chief Executive Officer, Chief Operating officer, President and Vice Chairman.
Senior executive with over 20 years experience in the OTC pharmaceutical field with broad ranging contract manufacturing oversight with most of the world’s top-20 research-based pharmaceutical companies. Nancy has been Director of New Business Development for Boehringer Ingelheim (Canada) Ltd. eventually becoming VP of the Consumer Health Division, and responsible for a vitamin and supplement manufacturing facility in Vancouver, B.C. She was VP of North American Business Management for Patheon Inc. responsible for customer relationships in Canada, the U.S. and Puerto Rico, maximizing product life cycle, reducing competitive threats, identifying line extensions, and making strategic manufacturing decisions.
Experienced executive at Novopharm Ltd. and Teva Pharmaceuticals Canada with over 35 years of progressive experience in the Pharmaceutical Industry. He has demonstrated expertise in all aspects of Pharmaceutical Analytical Research and Development and Quality Control Operations including but not limited to Analytical Method and Specifications Development and Validation, releasing of commercial Raw Materials and Finished Product batches, maintaining and trending Compliant Stability programs for North America, carrying out “Out of Specifications/Out of Trend” investigations and Analytical Methodology and Technology Transfers. Over his career, Tamas has developed a strong understanding and very close working relationships with Pharmaceutical Development, Regulatory Affairs (including Chemistry Manufacturing and Controls), Biopharmaceutics (PK/BA/BE) and QA Departments. Tamas has also served as an expert witness for Health Canada.
ldiko is an accomplished pharmaceutical executive with 30+ years of progressive experience and a strong portfolio of achievements. She has successfully led teams in different areas of pharmaceutical operations, including but not limited to pharmaceutical quality systems, scientific and technical affairs, analytical R&D, and quality control.
She has proven expertise in development and commercialization of both prescription and non-prescription pharmaceutical dosage forms and in understanding related regulatory requirements. She has supported over 70 regulatory submissions (chemistry and manufacturing controls) to different regulatory bodies in her past, resulting in drug approval and commercialization. She has maintained site compliance, led regulatory audits and just recently successfully guided her team to achieve EU GMP compliance for medicinal cannabis manufacturing, packaging and testing.
Her previously held roles include pharmaceutical quality, regulatory, compliance, general management at ARA – Avanti Rx Analytics Inc., Contract Pharmaceuticals Limited, Dalton Pharma Services, Taro Pharmaceuticals Inc., and Novopharm Ltd.
Dr. Fields has 20 years of experience within the pharmaceutical industry, where she headed the global clinical program at Apotex, overseeing scientific affairs, clinical and bioanalytical operations, as well as data management and clinical project management. Dr. Fields was also responsible for the development of clinical/regulatory strategies of the product pipeline. In an earlier role, Dr. Fields was responsible for providing scientific and regulatory guidance on all aspects of study design, statistical analysis, and reporting of bioequivalence and clinical equivalence studies of various dosage forms.
Keith is a finance professional with over 20 years of public company experience across a wide range of industries, including pharmaceuticals and manufacturing. In his previous role as Corporate Controller of Cynapsus Therapeutics, he was responsible for building the finance function of a clinical-stage pharmaceutical development company. He was instrumental in completing an uplisting on the TSX, a private equity placement, an IPO on NASDAQ, as well as the ultimate successful sale of the company. Other management level roles included Controller of Sublimity Therapeutics, Assistant Corporate Controller of SMTC and Audit Manager with PwC. Keith has considerable knowledge of financial reporting, controls, and regulatory compliance in both the US and Canada. A designated Chartered Professional Accountant, Keith earned his MAcc degree from the University of Waterloo.
Dave brings a wealth of global technology experience and knowledge from the financial and medical technology sectors, successfully developing, managing, and delivering technology solutions.
Dave is a graduate from McMaster University. He worked at XorGate Solutions Inc. as Sr. Solutions Architect, responsible for the technical development and support of artificial intelligence-based solutions. He also worked at Quadrant Biosciences – VP Canadian Operations responsible for the technical pre-sales, project management and delivery process development as well as post sales support. He also worked many years at Stryker Corp. as Business IT Leader in Global IS and was responsible for being the liaison between key global corporate functions and IT and was responsible for 100,000 plus licensed devices as part of Canadian establishment licence and all Health Canada Quality and reporting requirements.
Rindy is a Pharmaceutical professional with over 25 years of experience, having prior responsibilities for manufacturing, packaging, process improvement, facilities and project management. Prior to joining EmpowerPharm she was the Site Director at Pharmetics in Burlington. Before Pharmetics she was a Senior Operations Manager with Patheon Inc. Rindy’s past experience brings to EmpowerPharm a thorough knowledge across organizational departments and a solid team attitude allowing for effective guidance of multi-functional teams towards results. She brings a customer-centric focus ensuring quality services to both internal and external stakeholders which is key in her role as Site Director for EmpowerPharm. Rindy is a certified Professional Logistician (P.Log) with the Logistics Institute of Canada.
Giridhar Cheekati (Giri) is an industrial entrepreneur with 27 years of experience in Pharmaceutical & Natural Health Products industries with vast expertise in the areas of Pharmaceutics Research & Development, Commercial manufacturing, Validation, Product life cycle management, Quality Assurance & Compliance. In his past endeavors he was instrumental in integration of companies and technology transfer of novel branded formulations. Giri comes to Empower family with work experience in world renowned companies such as Cipla Ltd., Dr. Reddy’s Laboratories, Merck KGa&A, Mylan and Tilray.
Colin is a Pharmaceutical and Engineering professional that comes to us with over 15 years’ experience in the industry. Prior to joining EmpowerPharm he was the Engineering Manager at Contract Pharmaceuticals Limited where he crafted his skills in process design, continuous improvement, and statistical analysis. Colin brings a worldly view on manufacturing practices having started his career as an Engineer in Ireland with medical device company Boston Scientific.
Murray B Stein MD, MPH, FRCPC is Distinguished Professor of Psychiatry and Family Medicine & Public Health, Vice Chair for Clinical Research in Psychiatry at the University of California San Diego (UCSD), and a Staff Psychiatrist at the VA San Diego Healthcare System.
Dr. Stein graduated from the University of Manitoba and completed his residency and fellowship training at the University of Toronto and the NIMH in Bethesda, Maryland. He subsequently completed a Master of Public Health degree at the Johns Hopkins University Bloomberg School of Public Health.
Dr. Stein’s research interests include the epidemiology, neurobiology, and treatment of anxiety and trauma-related disorders including social anxiety disorder, posttraumatic stress disorder, and mild traumatic brain injury. He has written or co-written over 600 peer-reviewed scientific articles on these topics, including in journals such as JAMA and New England Journal of Medicine.
Dr. Stein is a Fellow of the American College of Neuropsychopharmacology and a Distinguished Fellow of the American Psychiatric Association. He is a past member of the APA DSM-5 Anxiety, OCD, and Trauma-Related Disorders Working Group (2009-2013), and of the FDA Psychopharmacologic Drugs Advisory Committee (2011-2016).
Dr. Stein is also Editor-in-Chief for the journal Depression and Anxiety, Co-Editor-in-Chief for UpToDate in Psychiatry, and Deputy Editor for the journal Biological Psychiatry.
Dr. Thiessen earned Pharmacy degrees in Canada and subsequently completed his doctoral studies at the University of California, San Francisco where he specialized in pharmacokinetics, pharmacodynamics, and experimental analytics. His academic career has involved ~40 years both at the Faculty of Pharmacy, University of Toronto and the University of Waterloo where he had strategic responsibility for developing the new Health Sciences campus including Canada’s 10th School of Pharmacy. In addition to the educator/leader role, his Canadian and International basic and clinical research has entailed time-dependent processes, drug response, new therapies in cancer and iron overload, and advanced technologies to diagnose and treat disease.
Beyond academics he has served organizations like the DQTC of the Ontario Ministry of Health, Health Canada’s Scientific Advisory Committee on Bioavailability, Bioequivalence, Pharmaceutical Sciences and Clinical Pharmacology, and the Waterloo-based Research Institute for Aging. His insights in fundamental research and clinical outcomes have brought numerous consulting opportunities in Canada, USA and Europe. Lastly, he remains academically linked as Professor Emeritus, University of Toronto and Adjunct Professor, University of Waterloo.
Dr. Antonio Vigano is the principal investigator for several medical-cannabis-related clinical trials, including the Quebec Cannabis Registry. He has extensive experience in the field of medical cannabis, having evaluated and monitored more than 1,500 medical cannabis patients since 2015.
As an expert in palliative medicine, Dr. Vigano is the director of the Cancer Rehabilitation and Cachexia Clinic at McGill University Health Centre and an Associate Professor at the Department of Oncology and Medicine at McGill University.
As a graduate of the University of Milan School of Medicine and the University of Alberta, Dr. Vigano has been the recipient of many awards, honours and distinctions over the course of his 30-year career.
Dr. Bhattacharyya is a Professor of Translational Neuroscience & Psychiatry at King’s College, London, UK. He is a pioneer researcher in the field of the effects of cannabinoids on different human brain functions. He has been part of international research groups focusing on different psychiatric and basic neuroscientific research regarding the interactions between the endocannabinoid system and human cognitive functions. Dr. Bhattacharyya specializes in neurobiology of schizophrenia, diagnostic imaging techniques and cannabinoids’ mechanism of action.
Dr. Van Ameringen is a full professor at the Psychiatry and Behavioural Neurosciences department at McMaster University. After graduating from medical school, he completed his residency in psychiatry and subspecialized in child psychiatry. His current research is focused on the psychopharmacology of anxiety disorders and comorbid mood disorders, obsessive compulsive and related disorders, the relationship between the gut microbiome and OCD, Social Anxiety Disorder, Generalized Anxiety Disorder and treatment resistance. He is a member of the Board of Directors and the Scientific Council of the Anxiety and Depression Association of America and is on the editorial board for the Journal of Depression and Anxiety. Dr. Van Ameringen has published widely in the area of OCD and anxiety disorders.
Dr. Arun Ravindran is a full Professor at the Department of Psychiatry, University of Toronto; he also is the director of global mental health project and the office of fellowship training of University of Toronto. He contributes to the Campbell Family Mental Health Research Institute at the Centre for Addiction and Mental Health as a research scientist. Dr. Ravindran’s clinical and research interests are in the area of mood and anxiety disorders. His research focus is on the behavioural pharmacology of psychotropic agents and their synergy with psychological and alternative therapies, and the use of functional neuroimaging to examine the etiology and treatment correlates of these illnesses. He has received the Donald A. Wasylenki Award for international partnerships, education and social responsibility from the Department of Psychiatry, University of Toronto. He enjoys contributing to humanitarian global mental health projects.